This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
'''2,5-Dimethoxy-4-propylthiophenethylamine''' (also known as '''2C-T-7''', '''Blue Mystic''',<ref name="microgram">Zimmerman, M.M., “The identification of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7).” Microgram, Vol. XXXIV, No. 7, July 2001, pp. 169-173.</ref> and '''Beautiful''',<ref name="microgram" /> among others) is a [[Psychoactive class::psychedelic]] substance of the [[Chemical class::phenethylamine]] chemical class that produces [[psychedelic]] and [[entactogenic]] effects when [[routes of administration|administered]].
'''2,5-Dimethoxy-4-propylthiophenethylamine''' (also known as '''2C-T-7''', '''Blue Mystic''',<ref name="microgram">{{cite magazine|last1=Zimmerman|first1=M. M.|title=The identification of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7)|work=Microgram|volume=XXXIV|number=7|date=July 2001|pages=169-173|publisher=Drug Enforcement Administration (DEA)}}</ref> and '''Beautiful''',<ref name="microgram" /> among others) is a [[Psychoactive class::psychedelic]] substance of the [[Chemical class::phenethylamine]] chemical class that produces [[psychedelic]] and [[entactogenic]] effects when [[routes of administration|administered]].
2C-T-7 was first synthesized by [[Alexander Shulgin]] and documented in his book [[PiHKAL]] ("Phenethylamines I Have Known and Loved").<ref>https://erowid.org/library/books_online/pihkal/pihkal.shtml | [[PiHKAL]] </ref> It is a member of the [[2C-x]] family of psychedelic phenethylamines, all of which were derived from the systematic modification of the [[mescaline]] molecule.
2C-T-7 was first synthesized by [[Alexander Shulgin]] and documented in his book [[PiHKAL]] ("Phenethylamines I Have Known and Loved").<ref name="PiHKAL">{{cite book|title=PiHKAL: A Chemical Love Story|title-link=PiHKAL|author-link1=Alexander Shulgin|author1=Alexander Shulgin|author2=Ann Shulgin|year=1991|publisher=Transform Press|location=United States|isbn=0963009605|oclc=1166889264|chapter-url=https://erowid.org/library/books_online/pihkal/pihkal043.shtml|chapter=#43. 2C-T-7}}</ref> It is a member of the [[2C-x]] family of psychedelic phenethylamines, all of which were derived from the systematic modification of the [[mescaline]] molecule.
In contrast to other members of the 2C-x family, 2C-T-7 has gained a reputation of being an unpredictable, dose-sensitive psychedelic capable of producing strong visual effects and an intense [[body load]], which can manifest as a dangerous delirium in extreme cases. Many reports indicate that the physical effects are too severe for inexperienced users or those with pre-existing medical conditions.
In contrast to other members of the 2C-x family, 2C-T-7 has gained a reputation of being an unpredictable, dose-sensitive psychedelic capable of producing strong visual effects and an intense [[body load]], which can manifest as a dangerous delirium in extreme cases. Many reports indicate that the physical effects are too severe for inexperienced users or those with pre-existing medical conditions.
This particular compound is part of the so-called "magical half-dozen" which refers to Shulgin's self-rated most important phenethylamine compounds, all of which -- with the exception of [[mescaline]] -- he designed, synthesized and tested on himself. They can be found within the first book of PiHKAL, and are as follows: [[Mescaline]], [[DOM]], [[2C-B]], [[2C-E]], [[2C-T-2]] and [[2C-T-7]].<ref>https://erowid.org/library/books_online/pihkal/pihkal.shtml | [[PiHKAL]] </ref>
This particular compound is part of the so-called "magical half-dozen" which refers to Shulgin's self-rated most important phenethylamine compounds, all of which -- with the exception of [[mescaline]] -- he designed, synthesized and tested on himself. They can be found within the first book of PiHKAL, and are as follows: [[Mescaline]], [[DOM]], [[2C-B]], [[2C-E]], [[2C-T-2]] and [[2C-T-7]].<ref>{{cite book|title=PiHKAL: A Chemical Love Story|author-link1=Alexander Shulgin|author1=Alexander Shulgin|author2=Ann Shulgin|year=1991|publisher=Transform Press|location=United States|isbn=0963009605|oclc=1166889264|url=https://erowid.org/library/books_online/pihkal/pihkal.shtml}}</ref>
==Chemistry==
==Chemistry==
Line 16:
Line 16:
2C-T-7 belongs to the 2C family of phenethylamines, which contain methoxy functional groups CH<sub>3</sub>O- attached to carbons R<sub>2</sub> and R<sub>5</sub> of the benzene ring. 2C-T-7 is also substituted at R<sub>4</sub> with a propyl thioether group.
2C-T-7 belongs to the 2C family of phenethylamines, which contain methoxy functional groups CH<sub>3</sub>O- attached to carbons R<sub>2</sub> and R<sub>5</sub> of the benzene ring. 2C-T-7 is also substituted at R<sub>4</sub> with a propyl thioether group.
2C-T-7 is analogous to 2C-T-2; the two differ by the length of the alkane chain in their thioether functional group.<ref>http://isomerdesign.com/PiHKAL/read.php?id=43</ref>
2C-T-7 is analogous to 2C-T-2; the two differ by the length of the alkane chain in their thioether functional group.<ref name="PiHKAL"/>
==Pharmacology==
==Pharmacology==
{{Further|Serotonergic psychedelic}}
{{Further|Serotonergic psychedelic}}
2C-T-7's [[psychedelic]] effects have been shown to come from its efficacy at the [[Serotonin#The 5-HT system|5-HT<sub>2A</sub> receptor]] as a [[Agonist#Agonists|partial agonist]].<ref>Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats | http://link.springer.com/article/10.1007%2Fs00213-005-0009-4</ref> However, the role of these interactions and how they result in the [[psychedelic]] experience continues to remain elusive.
2C-T-7's [[psychedelic]] effects have been shown to come from its efficacy at the [[Serotonin#The 5-HT system|5-HT<sub>2A</sub> receptor]] as a [[Agonist#Agonists|partial agonist]].<ref>{{cite journal|title=Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats|pmid=15983786|doi=10.1007/s00213-005-0009-4|first1=W. E.|last1=Fantegrossi|first2=A. W.|last2=Harrington|first3=J. R.|last3=Eckler|first4=S.|last4=Arshad|first5=R. A.|last5=Rabin|first6=J. C.|last6=Winter|first7=A.|last7=Coop|first8=K. C.|last8=Rice|first9=J. H.|last9=Woods|year=2005|volume=181|issue=3|pages=496-503|journal=Psychopharmacology|issn=0033-3158|eissn=1432-2072|oclc=2409222}}</ref> However, the role of these interactions and how they result in the [[psychedelic]] experience continues to remain elusive.
With serious adverse effects seen on overdoses of this compound (potentially [[Serotonin Syndrome]]) and as the 2,5-desmethoxy derivative of 2C-T-7 has been shown to be a moderate monoamine oxidase A inhibitor{{citation needed}} and many of the amphetamine-analogs of the [[2C-T-x]] series are highly selective MAO-A inhibitors (with [[ALEPH-7]] being one of the most potent), this substance is widely thought to also have [[MAOI]] effects.
With serious adverse effects seen on overdoses of this compound (potentially [[Serotonin Syndrome]]) and as the 2,5-desmethoxy derivative of 2C-T-7 has been shown to be a moderate monoamine oxidase A inhibitor<ref name="WagmannBrandt2019">{{cite journal|last1=Wagmann|first1=Lea|last2=Brandt|first2=Simon D.|last3=Stratford|first3=Alexander|last4=Maurer|first4=Hans H.|last5=Meyer|first5=Markus R.|title=Interactions of phenethylamine-derived psychoactive substances of the 2C-series with human monoamine oxidases|journal=Drug Testing and Analysis|volume=11|issue=2|year=2019|pages=318–324|issn=19427603|doi=10.1002/dta.2494}}</ref> and many of the amphetamine-analogs of the [[2C-T-x]] series are highly selective MAO-A inhibitors (with [[ALEPH-7]] being one of the most potent)<ref>{{cite journal|title=Sulfur-Substituted α-Alkyl Phenethylamines as Selective and Reversible MAO-A Inhibitors: Biological Activities, CoMFA Analysis, and Active Site Modeling|doi=10.1021/jm0493109|pmid=15801832|url=http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.689.281&rep=rep1&type=pdf|first1=A.|last1=Gallardo-Godoy|first2=A.|last2=Fierro|first3=T. H.|last3=McLean|first4=M.|last4=Castillo|first5=B. K.|last5=Cassels|first6=M.|last6=Reyes-Parada|first7=D. E.|last7=Nichols|author-link7=David E. Nichols|year=2005|volume=48|issue=7|pages=2407–2419|journal=Journal of Medicinal Chemistry|issn=0022-2623|eissn=1520-4804|oclc=39480771}}</ref>, this substance is widely thought to also have [[MAOI]] effects.
==Subjective effects==
==Subjective effects==
Line 120:
Line 120:
{{toxicity}}
{{toxicity}}
{{further|Research chemicals#Toxicity and harm potential|Responsible use #Hallucinogens}}
{{further|Research chemicals#Toxicity and harm potential|Responsible use #Hallucinogens}}
As of August 2007, there have been at least three reported deaths associated with the use of 2C-T-7. These incidents occurred with insufflated doses of 30 mg or more<ref>Curtis, B., Kemp, P., Harty, L., Choi, C., & Christensen, D. (2003). Postmortem identification and quantitation of 2, 5-dimethoxy-4-n-propylthiophenethylamine using GC-MSD and GC-NPD. Journal of analytical toxicology, 27(7), 493-498.</ref>, or in combination with stimulants such as MDMA,{{citation needed}}. There have also been a number of reports describing concerning physical side effects and hospitalizations, typically following insufflation.<ref name="T74">2C-T-7 Overdoses & Delirium | https://www.erowid.org/chemicals/2ct7/2ct7_effects.shtml#overdose</ref>
As of August 2007, there have been at least three reported deaths associated with the use of 2C-T-7. These incidents occurred with insufflated doses of 30 mg or more<ref>{{cite journal|last1=Curtis|first1=B.|last2=Kemp|first2=P.|last3=Harty|first3=L.|last4=Choi|first4=C.|last5=Christensen|first5=D.|year=2003|title=Postmortem Identification and Quantitation of 2,5-Dimethoxy-4-n-propylthiophenethylamine Using GC-MSD and GC-NPD|journal=Journal of Analytical Toxicology|volume=27|issue=7|pages=493-498|pmid=14607005|doi=10.1093/jat/27.7.493|issn=0146-4760|eissn=1945-2403|oclc=02942106}}</ref>, or in combination with stimulants such as MDMA,{{citation needed}}. There have also been a number of reports describing concerning physical side effects and hospitalizations, typically following insufflation.<ref name="T74">{{cite web|title=2C-T-7 Overdoses & Delirium|url=https://www.erowid.org/chemicals/2ct7/2ct7_effects.shtml#overdose|publisher=Erowid|date=June 15, 2000}}</ref>
It is strongly discouraged to administer 2C-T-7 non-orally because this can cause vomiting, numerous negative side effects, or death at high doses. In Erowid's Fall 2000 2C-T-7 survey, it was reported that the [[insufflation]] of 2C-T-7 resulted in more negative side effects than oral administration.{{citation needed}}
It is strongly discouraged to administer 2C-T-7 non-orally because this can cause vomiting, numerous negative side effects, or death at high doses. In Erowid's Fall 2000 2C-T-7 survey, it was reported that the [[insufflation]] of 2C-T-7 resulted in more negative side effects than oral administration.{{citation needed}}
Line 129:
Line 129:
2C-T-7 is [[Addiction potential::not habit-forming]] and the desire to use it can actually decrease with use. It is most often self-regulating.
2C-T-7 is [[Addiction potential::not habit-forming]] and the desire to use it can actually decrease with use. It is most often self-regulating.
Tolerance to the effects of 2C-T-7 are built [[Time to full tolerance::almost immediately after ingestion]]. After that, it takes about [[Time to half tolerance::3 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::7 days]] to be back at baseline (in the absence of further consumption). 2C-T-7 presents cross-tolerance with [[Cross-tolerance::all [[psychedelic]]s]], meaning that after the consumption of 2C-T-7 all psychedelics will have a reduced effect.
Tolerance to the effects of 2C-T-7 is built [[Time to full tolerance::almost immediately after ingestion]]. After that, it takes about [[Time to half tolerance::3 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::7 days]] to be back at baseline (in the absence of further consumption). 2C-T-7 presents cross-tolerance with [[Cross-tolerance::all [[psychedelic]]s]], meaning that after the consumption of 2C-T-7 all psychedelics will have a reduced effect.
===Dangerous interactions===
===Dangerous interactions===
{{DangerousInteractions/Intro}}
{{DangerousInteractions/Intro}}
If 2C-T-7 does have [[MAOI]] effects as commonly speculated, this could indicate that 2C-T-7 is more likely to induce [[serotonin syndrome]] or general [[neurotransmitter]] overload (especially at high dosages) than other [[serotonergic psychedelic]]s.<ref>Sulfur-Substituted α-Alkyl Phenethylamines as Selective and Reversible MAO-A Inhibitors: Biological Activities, CoMFA Analysis, and Active Site Modeling | http://pubs.acs.org/doi/abs/10.1021/jm0493109</ref> This may make it dangerous to combine it with other [[MAOI]]s, [[stimulant]]s and certain substances which releases neurotransmitters such as [[serotonin]] or [[dopamine]]. These substances include but are not limited to:
If 2C-T-7 does have [[MAOI]] effects as commonly speculated, this could indicate that 2C-T-7 is more likely to induce [[serotonin syndrome]] or general [[neurotransmitter]] overload (especially at high dosages) than other [[serotonergic psychedelic]]s.<ref>{{cite journal|title=Sulfur-Substituted α-Alkyl Phenethylamines as Selective and Reversible MAO-A Inhibitors: Biological Activities, CoMFA Analysis, and Active Site Modeling|doi=10.1021/jm0493109|pmid=15801832|url=http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.689.281&rep=rep1&type=pdf|first1=A.|last1=Gallardo-Godoy|first2=A.|last2=Fierro|first3=T. H.|last3=McLean|first4=M.|last4=Castillo|first5=B. K.|last5=Cassels|first6=M.|last6=Reyes-Parada|first7=D. E.|last7=Nichols|author-link7=David E. Nichols|year=2005|volume=48|issue=7|pages=2407–2419|journal=Journal of Medicinal Chemistry|issn=0022-2623|eissn=1520-4804|oclc=39480771}}</ref> This may make it dangerous to combine it with other [[MAOI]]s, [[stimulant]]s and certain substances which releases neurotransmitters such as [[serotonin]] or [[dopamine]]. These substances include but are not limited to:
{|
{|
|-
|-
Line 168:
Line 168:
==Legal status==
==Legal status==
*'''Australia''' - In Australia, 2C-T-2 and 2C-T-7 are covered by the country's analog drug laws.{{citation needed}}
In November 2003, the European Council decided that 2C-T-7 shall be subjected by the Member States to control measures and criminal penalties within three months.<ref>{{cite magazine|url=http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2003:321:0064:0065:EN:PDF|title=COUNCIL DECISION 2003/847/JHA|date=November 27, 2003|publication-date=December 6, 2003|work=Official Journal of the European Union|pages=64-65|id=L 321|publisher=Office for Official Publications of the European Communites|oclc=52224955}}</ref>
*'''Austria:''' 2C-T-7 is illegal to possess, produce and sell under the SMG. (Suchtmittelgesetz Österreich)
*'''Brazil''' - Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.<ref>http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7</ref>
*'''Australia''': In Australia, 2C-T-2 and 2C-T-7 are covered by the country's analog drug laws.{{citation needed}}
*'''Canada:''' 2C-T-7 is considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.<ref>Controlled Drugs and Substances Act (S.C. 1996, c. 19) |http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-12.html#h-28</ref>
*'''Austria''': 2C-T-7 is illegal to possess, produce and sell under the SMG. (Suchtmittelgesetz Österreich){{citation needed}}
*'''China''' - As of October 2015 2C-T-7 is a controlled substance in China.<ref>{{cite web | url=http://www.sfda.gov.cn/WS01/CL0056/130753.html | title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | publisher=China Food and Drug Administration | date=27 September 2015 | language=Chinese | accessdate=1 October 2015}}</ref>
*'''Brazil''': Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.<ref>{{cite web|url=http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7|title=RESOLUÇÃO DA DIRETORIA COLEGIADA - RDC N° 130, DE 2 DE DEZEMBRO DE 2016|publication-date=December 5, 2016|publisher=Agência Nacional de Vigilância Sanitária (ANVISA) [Brazilian Health Regulatory Agency (ANVISA)]|language=pt}}</ref>
*'''Germany''' - Possession, production and sale is illegal.<ref>BtMG Anlage I | https://www.gesetze-im-internet.de/btmg_1981/anlage_i.html </ref>
*'''Canada''': 2C-T-7 is considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.<ref>{{cite web|url=http://isomerdesign.com/Cdsa/schedule.php?schedule=3§ion=ALL&structure=C|title=Schedule III|work=Controlled Drugs and Substances Act (CDSA)|publisher=Isomer Design|access-date=October 10, 2020}}</ref>
*'''Latvia''' - 2C-T-7 is a Schedule I controlled substance in Latvia.<ref>Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2,5-Dimetoksifeniletānamīni) | http://likumi.lv/doc.php?id=121086</ref>
*'''China''': As of October 2015 2C-T-7 is a controlled substance in China.<ref>{{cite web|url=http://www.sfda.gov.cn/WS01/CL0056/130753.html|title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知|publisher=国家食品药品监督管理总局 [China Food and Drug Administration (CFDA)]|date=September 27, 2015|language=zh|archive-url=https://web.archive.org/web/20170906191704/http://www.sfda.gov.cn/WS01/CL0056/130753.html|archive-date=September 6, 2017}}</ref>
*'''Netherlands''' - The Netherlands was the first country in the world to ban 2C-T-7 after being sold in smart shops for a short period. After 2C-T-2 was first banned, 2C-T-7 quickly appeared on the market but was soon banned as well. 2C-T-7 is a list I drug of the Opium Law.{{citation needed}}
*'''Germany''': 2C-T-7 is controlled under Anlage I BtMG (''Narcotics Act, Schedule I'')<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/anlage_i.html|title=Gesetz über den Verkehr mit Betäubungsmitteln: Anlage I|publisher=Bundesamt für Justiz [Federal Office of Justice]|access-date=December 10, 2019|language=de}}</ref> as of July 1, 2001.<ref>{{cite web|url=http://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl101s1180.pdf|title=Fünfzehnte Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften|publisher=Bundesanzeiger Verlag|work=Bundesgesetzblatt Jahrgang 2001 Teil I Nr. 28|pages=1180-1201|publication-date=June 25, 2001|language=de|oclc=231871244|issn=0341-1095|date=June 19, 2001}}</ref> It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/__29.html|title=Gesetz über den Verkehr mit Betäubungsmitteln: § 29|publisher=Bundesamt für Justiz [Federal Office of Justice]|access-date=December 10, 2019|language=de}}</ref>
*'''Sweden''' - The drug is Schedule I in Sweden.<ref>http://www.lakemedelsverket.se/upload/lvfs/LVFS_2004-3.pdf</ref> 2C-T-7 was first classified as a health hazard under the act "Lagen om förbud mot vissa hälsofarliga varor" (translated as "the Act on the Prohibition of Certain Goods Dangerous to Health") that made it illegal to sell or possess as of April 1, 1999.{{citation needed}}
*'''Latvia''': 2C-T-7 is a Schedule I controlled substance in Latvia.<ref>{{cite web|url=http://likumi.lv/doc.php?id=121086|title=Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem|publisher=VSIA Latvijas Vēstnesis|access-date=January 1, 2020|publication-date=November 10, 2005|language=lv}}</ref>
*'''Switzerland:''' Possession, production and sale is illegal.<ref>http://web.archive.org/web/20170329020935/https://www.admin.ch/opc/de/classified-compilation/20101220/index.html</ref>
*'''The Netherlands''': The Netherlands was the first country in the world to ban 2C-T-7 after being sold in smart shops for a short period. After 2C-T-2 was first banned, 2C-T-7 quickly appeared on the market but was soon banned as well. 2C-T-7 is a list I drug of the Opium Law.{{citation needed}}
*'''United Kingdom''' - 2C-T-7 is a Class A drug in the United Kingdom as a result of the phenethylamine catch-all clause.<ref>United Kingdom. (1977). Misuse of Drugs Act 1971 (S.I. 1977/1243). London: The Stationery Office Limited. Retrieved July 5, 2017, from http://www.legislation.gov.uk/uksi/1977/1243/made</ref>
*'''Sweden''': The drug is Schedule I in Sweden.<ref>{{cite web|url=http://www.lakemedelsverket.se/upload/lvfs/LVFS_2004-3.pdf|archive-url=https://web.archive.org/web/20180613184606/http://www.lakemedelsverket.se/upload/lvfs/LVFS_2004-3.pdf|archive-date=June 13, 2018|title=Föreskrifter om ändring i Läkemedelsverkets föreskrifter (LVFS 1997:12) om förteckningar över narkotika|date=February 24, 2004|id=LVFS 2004:3|publication-date=March 16, 2004|issn=1101-5225|publisher=Läkemedelsverket [Medical Products Agency]|language=sv}}</ref> 2C-T-7 was first classified as a health hazard under the act "Lagen om förbud mot vissa hälsofarliga varor" (translated as "the Act on the Prohibition of Certain Goods Dangerous to Health") that made it illegal to sell or possess as of April 1, 1999.{{citation needed}}
*'''United States''' - On September 20, 2002, 2C-T-7 was classified as a Schedule I substance in the United States by an emergency ruling by the DEA. On March 18, 2004, the DEA published a final rule in the Federal Register which permanently placed 2C-T-7 in Schedule I.{{citation needed}}
*'''Switzerland''': 2C-T-7 is a controlled substance specifically named under Verzeichnis D.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref>
*'''United Kingdom''': 2C-T-7 is a Class A drug in the United Kingdom as a result of the phenethylamine catch-all clause.<ref>{{cite web|title=Schedule 2: Part I: Class A Drugs|url=http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I|work="Misuse of Drugs Act 1971"|access-date=August 20, 2020|publisher=UK Government}}</ref>
*'''United States''': On September 20, 2002, 2C-T-7 was classified as a Schedule I substance in the United States by an emergency ruling by the DEA. On March 18, 2004, the DEA published a final rule in the Federal Register which permanently placed 2C-T-7 in Schedule I.{{citation needed}}
==See also==
==See also==
Line 203:
Line 205:
==References==
==References==
<references/>
<references/>
[[Category:Psychoactive substance]]
[[Category:Psychoactive substance]]
[[Category:Psychedelic]]
[[Category:2C-T-x]]
[[Category:Research chemical]]
[[Category:Research chemical]]
[[Category:Phenethylamine]]
[[Category:Psychedelic]]
{{#set:Featured=true
{{#set:Featured=true
|RN=
|RN=
Latest revision as of 23:09, 29 May 2021
Serious injury or death may occur if 2C-T-7 is insufflated or combined with certain substances and medications (e.g. MAOIs or RIMAs)[1][2][3]
WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.
DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.
2C-T-7 was first synthesized by Alexander Shulgin and documented in his book PiHKAL ("Phenethylamines I Have Known and Loved").[5] It is a member of the 2C-x family of psychedelic phenethylamines, all of which were derived from the systematic modification of the mescaline molecule.
In contrast to other members of the 2C-x family, 2C-T-7 has gained a reputation of being an unpredictable, dose-sensitive psychedelic capable of producing strong visual effects and an intense body load, which can manifest as a dangerous delirium in extreme cases. Many reports indicate that the physical effects are too severe for inexperienced users or those with pre-existing medical conditions.
This particular compound is part of the so-called "magical half-dozen" which refers to Shulgin's self-rated most important phenethylamine compounds, all of which -- with the exception of mescaline -- he designed, synthesized and tested on himself. They can be found within the first book of PiHKAL, and are as follows: Mescaline, DOM, 2C-B, 2C-E, 2C-T-2 and 2C-T-7.[6]
2C-T-7, or 2,5-dimethoxy-4-propylthiophenethylamine, is a substituted phenethylamine featuring a phenyl ring bound to an amino (NH2) group through an ethyl chain.
2C-T-7 belongs to the 2C family of phenethylamines, which contain methoxy functional groups CH3O- attached to carbons R2 and R5 of the benzene ring. 2C-T-7 is also substituted at R4 with a propyl thioether group.
2C-T-7 is analogous to 2C-T-2; the two differ by the length of the alkane chain in their thioether functional group.[5]
2C-T-7's psychedelic effects have been shown to come from its efficacy at the 5-HT2A receptor as a partial agonist.[7] However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.
With serious adverse effects seen on overdoses of this compound (potentially Serotonin Syndrome) and as the 2,5-desmethoxy derivative of 2C-T-7 has been shown to be a moderate monoamine oxidase A inhibitor[8] and many of the amphetamine-analogs of the 2C-T-x series are highly selective MAO-A inhibitors (with ALEPH-7 being one of the most potent)[9], this substance is widely thought to also have MAOI effects.
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWikicontributors. As a result, they should be viewed with a healthy degree of skepticism.
It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.
Physical effects
Stimulation - In terms of its effects on the physical energy levels of the user, 2C-T-7 is generally considered to be energetic and stimulating in a fashion is comparable to that of other phenethylamines such as 2C-B, 2C-E and 2C-P. However, at certain doses and contexts, it may produce periods of notable sedation.
Spontaneous physical sensations - The "body high" of 2C-T-7 is intense, but in comparison to 2C-E or 2C-B, it can be considered mild though is still capable of becoming very powerful and highly physically euphoric. It is similar yet distinct from the "body high" experienced on 2C-E, 2C-B, and LSD. The sensation itself can be described as intense and will manifest itself in the form of a continuously shifting tingling sensation that travels up and down the body in spontaneous waves.
Bodily control enhancement - Although this component is capable of manifesting itself in a distinct and noticeable fashion, for most users it does not generally seem to be as apparent or intense as the same component found within LSD and 2C-B.
Nausea - Mild to extreme nausea is commonly reported when consumed in moderate to high dosages, and either passes once the user has vomited or gradually fades by itself as the peak sets in.
Drifting(melting, flowing, breathing and morphing) - In comparison to other psychedelics, this effect can be described as highly detailed, slow and smooth in motion, static in appearance and extremely realistic in style but with a subtle digital/cartoonish form.
The visual geometry that is present throughout this trip can be described as more similar in appearance to that of 4-AcO-DMT or ayahuasca than that of LSD, 2C-B or 2C-I. They can be comprehensively described as structured in their organization, organic in geometric style, intricate in complexity, large, fast and smooth in motion, colorful in scheme, glossy in color, sharp in their edges and equally rounded and angular in their corners. It gives off a contradictory natural and synthetic feel with slightly more mystical and shamanic undertones in comparison to other phenethylamines. At higher dosages, they are equally likely to result in states of Level 8A visual geometry or Level 8B. There seems to be a visual geometry that is extremely similar to 2C-E and 2C-P and can be described as equal in intensity or complexity and equal in proportion to the accompanying cognitive and physical effects.
Hallucinatory states
2C-T-7 produces a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of many other commonly used psychedelics. This holds particularly true in comparison to other substances within the phenethylamine family. These effects include:
Internal hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots) - This effect is very consistent in dark environments at appropriately high dosages. They can be comprehensively described through their variations as lucid in believability, interactive in style, new experiences in content, autonomous in controllability, geometry-based in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme.
Cognitive effects
The head space of 2C-T-7 is described by many as one which is both insightful and relatively normal in its thought processes even at moderate to high dosages.
There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:
This toxicity and harm potential section is a stub.
As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it. Note: Always conduct independent research and use harm reduction practices if using this substance.
As of August 2007, there have been at least three reported deaths associated with the use of 2C-T-7. These incidents occurred with insufflated doses of 30 mg or more[10], or in combination with stimulants such as MDMA,[citation needed]. There have also been a number of reports describing concerning physical side effects and hospitalizations, typically following insufflation.[11]
It is strongly discouraged to administer 2C-T-7 non-orally because this can cause vomiting, numerous negative side effects, or death at high doses. In Erowid's Fall 2000 2C-T-7 survey, it was reported that the insufflation of 2C-T-7 resulted in more negative side effects than oral administration.[citation needed]
It is strongly recommended that one use harm reduction practices, such as volumetric dosing, when using this substance to ensure the accurate administration of the intended dose.
Tolerance and addiction potential
2C-T-7 is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.
Tolerance to the effects of 2C-T-7 is built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). 2C-T-7 presents cross-tolerance with [[Cross-tolerance::all psychedelics]], meaning that after the consumption of 2C-T-7 all psychedelics will have a reduced effect.
Dangerous interactions
Warning:Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
If 2C-T-7 does have MAOI effects as commonly speculated, this could indicate that 2C-T-7 is more likely to induce serotonin syndrome or general neurotransmitter overload (especially at high dosages) than other serotonergic psychedelics.[12] This may make it dangerous to combine it with other MAOIs, stimulants and certain substances which releases neurotransmitters such as serotonin or dopamine. These substances include but are not limited to:
In November 2003, the European Council decided that 2C-T-7 shall be subjected by the Member States to control measures and criminal penalties within three months.[13]
Australia: In Australia, 2C-T-2 and 2C-T-7 are covered by the country's analog drug laws.[citation needed]
Austria: 2C-T-7 is illegal to possess, produce and sell under the SMG. (Suchtmittelgesetz Österreich)[citation needed]
Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.[14]
Canada: 2C-T-7 is considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.[15]
China: As of October 2015 2C-T-7 is a controlled substance in China.[16]
Germany: 2C-T-7 is controlled under Anlage I BtMG (Narcotics Act, Schedule I)[17] as of July 1, 2001.[18] It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.[19]
Latvia: 2C-T-7 is a Schedule I controlled substance in Latvia.[20]
The Netherlands: The Netherlands was the first country in the world to ban 2C-T-7 after being sold in smart shops for a short period. After 2C-T-2 was first banned, 2C-T-7 quickly appeared on the market but was soon banned as well. 2C-T-7 is a list I drug of the Opium Law.[citation needed]
Sweden: The drug is Schedule I in Sweden.[21] 2C-T-7 was first classified as a health hazard under the act "Lagen om förbud mot vissa hälsofarliga varor" (translated as "the Act on the Prohibition of Certain Goods Dangerous to Health") that made it illegal to sell or possess as of April 1, 1999.[citation needed]
Switzerland: 2C-T-7 is a controlled substance specifically named under Verzeichnis D.[22]
United Kingdom: 2C-T-7 is a Class A drug in the United Kingdom as a result of the phenethylamine catch-all clause.[23]
United States: On September 20, 2002, 2C-T-7 was classified as a Schedule I substance in the United States by an emergency ruling by the DEA. On March 18, 2004, the DEA published a final rule in the Federal Register which permanently placed 2C-T-7 in Schedule I.[citation needed]
↑ 4.04.1Zimmerman, M. M. (July 2001). "The identification of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7)". Microgram. Vol. XXXIV (7). Drug Enforcement Administration (DEA). pp. 169–173.
↑Fantegrossi, W. E.; Harrington, A. W.; Eckler, J. R.; Arshad, S.; Rabin, R. A.; Winter, J. C.; Coop, A.; Rice, K. C.; Woods, J. H. (2005). "Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats". Psychopharmacology. 181 (3): 496–503. doi:10.1007/s00213-005-0009-4. eISSN1432-2072. ISSN0033-3158. OCLC2409222. PMID15983786.
↑Wagmann, Lea; Brandt, Simon D.; Stratford, Alexander; Maurer, Hans H.; Meyer, Markus R. (2019). "Interactions of phenethylamine-derived psychoactive substances of the 2C-series with human monoamine oxidases". Drug Testing and Analysis. 11 (2): 318–324. doi:10.1002/dta.2494. ISSN1942-7603.
↑"COUNCIL DECISION 2003/847/JHA". Official Journal of the European Union. Office for Official Publications of the European Communites (published December 6, 2003). November 27, 2003. pp. 64–65. OCLC52224955. L 321.
↑"Schedule III". Controlled Drugs and Substances Act (CDSA). Isomer Design. Retrieved October 10, 2020.
↑"关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in 中文). 国家食品药品监督管理总局 [China Food and Drug Administration (CFDA)]. September 27, 2015. Archived from the original on September 6, 2017.
